Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Ferrante

Showing results (161-170 of 350) with videos related to

Pageof 35
Sort By:
European Journal of Gastroenterology & Hepatology|April 12, 2022
Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational studyMarc Ferrante, Anja Schirbel, Marieke J Pierik, et al.
Ebiomedicine|January 28, 2019
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel diseaseBram Verstockt, Sare Verstockt, Jonas Dehairs, et al.
Inflammatory Bowel Diseases|July 29, 2009
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case seriesMarc Ferrante, Geert D'Haens, Olivier Dewit, et al.
Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genesMarc Ferrante, Sarah Declerck, Tamara Coopmans, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2020
Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic TherapiesPauline Rivière, Séverine Vermeire, Marie Irles-Depe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 26, 2019
Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel DiseasesBram Verstockt, Sare Verstockt, Marisol Veny, et al.
Inflammatory Bowel Diseases|September 7, 2006
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel diseaseMarc Ferrante, Marie Pierik, Liesbet Henckaerts, et al.
Journal of Crohn'S & Colitis|October 19, 2021
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's DiseaseNeeraj Narula, Emily C L Wong, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|April 3, 2009
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's diseaseFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.
Pageof 35

Showing results (161-170 of 350) with videos related to

Sort By:
Pageof 35
European Journal of Gastroenterology & Hepatology|April 12, 2022
Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational studyMarc Ferrante, Anja Schirbel, Marieke J Pierik, et al.
Ebiomedicine|January 28, 2019
Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel diseaseBram Verstockt, Sare Verstockt, Jonas Dehairs, et al.
Inflammatory Bowel Diseases|July 29, 2009
Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case seriesMarc Ferrante, Geert D'Haens, Olivier Dewit, et al.
Journal of Crohn'S & Colitis|September 10, 2015
A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's DiseaseThomas Billiet, Konstantinos Papamichael, Magali de Bruyn, et al.
Journal of Crohn'S & Colitis|December 22, 2010
Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genesMarc Ferrante, Sarah Declerck, Tamara Coopmans, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2020
Rates of Postoperative Recurrence of Crohn's Disease and Effects of Immunosuppressive and Biologic TherapiesPauline Rivière, Séverine Vermeire, Marie Irles-Depe, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 26, 2019
Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel DiseasesBram Verstockt, Sare Verstockt, Marisol Veny, et al.
Inflammatory Bowel Diseases|September 7, 2006
The role of vascular endothelial growth factor (VEGF) in inflammatory bowel diseaseMarc Ferrante, Marie Pierik, Liesbet Henckaerts, et al.
Journal of Crohn'S & Colitis|October 19, 2021
Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's DiseaseNeeraj Narula, Emily C L Wong, Jean-Frederic Colombel, et al.
Inflammatory Bowel Diseases|April 3, 2009
Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's diseaseFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.
Pageof 35